Cancer Biopsy Market Report and Forecast 2024-2032

The global cancer biopsy market size was valued at USD 28.7 billion in 2023, driven by advancements in technology and a growing preference for procedures with lower risk and discomfort across the globe. The market size is anticipated to grow at a CAGR of 13.2% during the forecast period of 2024-2032 to achieve a value of USD 87.4 billion by 2032.

Cancer Biopsy: Introduction

Cancer biopsy is a critical diagnostic procedure in oncology, involving the collection of a small sample of tissue or cells from a suspected cancerous area for examination. This sample is then analyzed under a microscope by pathologists to determine the presence and type of cancer, its aggressiveness, and other important characteristics that can guide treatment decisions. Biopsies can be performed through various methods, including needle aspiration, endoscopic biopsy, or surgical removal of tissue, depending on the location and accessibility of the tumour. The procedure is instrumental not only in confirming a cancer diagnosis but also in staging the cancer and planning an appropriate course of treatment.

In recent years, the advent of molecular and genetic testing on biopsy samples has further enhanced the diagnostic power, allowing for more personalized and targeted therapy options. Cancer biopsy remains a cornerstone in cancer management, providing vital information that shapes patient care and outcomes.

Key Trends in the Global Cancer Biopsy Market

The global Cancer Biopsy market was experiencing several key trends that were shaping its landscape. Firstly, there was an increasing shift towards minimally invasive biopsy techniques, such as liquid biopsies and fine-needle aspirations, driven by advancements in technology and a growing preference for procedures with lower risk and discomfort. Precision medicine was a significant trend, with a rising focus on molecular and genetic profiling of biopsy samples to enable more targeted and personalized cancer therapies. The integration of artificial intelligence and machine learning in analyzing biopsy samples was gaining traction, enhancing diagnostic accuracy and efficiency. There was also a growing emphasis on companion diagnostics, where biopsies are used to identify specific biomarkers that can predict the efficacy of certain treatments.

While North America and Europe continued to dominate the market, regions such as Asia Pacific were witnessing rapid growth due to increasing cancer prevalence, improving healthcare infrastructure, and rising awareness. However, challenges such as the high cost of advanced biopsy procedures and the need for skilled professionals to perform and interpret biopsies were also prevalent. Overall, these trends indicated a dynamic and evolving market, reflecting the ongoing advancements and the crucial role of cancer biopsies in oncology.

Global Cancer Biopsy Market Segmentation

Market Breakup by Product and Services

• Kits and Consumables
• Instruments
• Services

Market Breakup by Type

• Needle Biopsy
• Skin Biopsies
• Bone Marrow Biopsies
• Liquid Biopsies
• Other Biopsies

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Global Cancer Biopsy Market Overview

The growth of the market was primarily fuelled by the increasing global incidence of cancer and the critical role of biopsies in cancer diagnosis, staging, and treatment planning. North America held a dominant position in the market, supported by advanced healthcare infrastructure, high healthcare expenditure, and the presence of leading biotechnology and diagnostic companies. Europe also accounted for a significant share, driven by robust healthcare systems and increasing cancer awareness. The Asia Pacific region was emerging as a rapidly growing market due to rising cancer prevalence, growing healthcare infrastructure, and increasing adoption of advanced diagnostic methods. The market featured a range of biopsy techniques, including traditional surgical biopsies, minimally invasive procedures, and innovative liquid biopsies.

Advancements in precision medicine and the development of molecular and genetic profiling techniques were further propelling the market. Despite the growth, challenges such as disparities in access to advanced diagnostic facilities in low- and middle-income countries and the high cost of certain biopsy procedures persisted. Overall, the global Cancer Biopsy market was poised for continued expansion, underlined by the indispensable role of biopsies in comprehensive cancer care.

Global Cancer Biopsy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• QIAGEN
• Illumina, Inc.
• ANGLE plc
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories Inc.
• Hologic, Inc.
• BIOCEPT, INC.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher

The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


This product will be delivered within 5-7 business days.